文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

低剂量吸入一氧化碳治疗特发性肺纤维化的II期临床试验

A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis.
PubMed 文献 · Chest · 2017-10-31
一句话结论多中心IIa期双盲假对照试验显示,特发性肺纤维化患者每日吸入100–200 ppm一氧化碳2小时、每周2次、共12周可耐受,但未显著改变血清MMP7等终点。

该多中心IIa期双盲假对照试验将58例特发性肺纤维化患者随机分为吸入一氧化碳100–200 ppm组(n=29)与吸入21%氧气假对照组(n=29),每日2小时、每周2次、共12周。主要终点为12周后血清基质金属蛋白酶-7(MMP7)浓度变化差异,结果两组间无显著差异(第12周MMP7差值-0.90 ng/mL,95%CI -4.18至2.38 ng/mL)。肺功能、6分钟步行距离、急性加重、住院、死亡及生活质量等次要终点均无差异,不良事件分布两组间无差异。结论认为吸入一氧化碳在门诊环境中可安全耐受,但未显著改变研究终点。

要点

  • 58例IPF患者随机接受吸入CO 100–200 ppm(n=29)或吸入21%氧气(n=29),每日2小时、每周2次、共12周。
  • 主要终点血清MMP7第12周变化两组间无显著差异:差值-0.90 ng/mL(95%CI -4.18至2.38 ng/mL)。
  • 肺功能、6分钟步行距离、急性加重、住院、死亡及患者报告结局均无差异。
  • 不良事件分布两组间无差异,吸入CO在门诊环境中可安全耐受。
  • 作者认为研究结果支持在未来IPF临床试验中测试吸入疗法的疗效。

适用人群与场景

  • 特发性肺纤维化(IPF)患者,在门诊环境接受治疗。

处置流程与药物剂量

  • 吸入一氧化碳100–200 ppm或吸入21%氧气,每日2小时、每周2次、共12周。

研究设计与关键结果

  • 多中心、IIa期、双盲、假对照临床试验,58例IPF患者随机分为吸入CO组(n=29)与假对照组(n=29)。
  • 主要终点:12周后血清MMP7浓度变化两组间无显著差异(差值-0.90 ng/mL,95%CI -4.18至2.38 ng/mL)。
  • 次要终点:肺功能、6分钟步行距离、急性加重发生率、住院、死亡及患者报告结局均无差异。
  • 不良事件分布两组间无差异,吸入CO可安全耐受。

证据类型、等级与局限

  • 证据类型:多中心IIa期双盲假对照临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为吸入CO在门诊环境中可安全耐受地给予IPF患者,但未显著改变研究终点。
  • 作者认为研究结果支持在未来IPF临床试验中测试吸入疗法的疗效。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Preclinical studies have demonstrated that low-dose carbon monoxide (CO) can abrogate experimental lung fibrosis. To test the therapeutic role of inhaled CO, we designed a clinical study in patients with idiopathic pulmonary fibrosis (IPF).

METHODS: We conducted a multicenter, phase IIa, double-blinded, sham-controlled, clinical trial. Patients with IPF were randomized to treatment with inhaled CO at 100 to 200 parts per million or to inhaled 21% oxygen for 2 h daily, twice weekly, for 12 weeks. The primary study end point was the difference in change in matrix metalloproteinase-7 (MMP7) serum concentration after 12 weeks of treatment. Secondary end points included pulmonary function test measures, 6-min walk distance, rates of adverse events, acute exacerbation, hospitalization and death, and quality of life measures.

RESULTS: Fifty-eight subjects were randomized to treatment with inhaled CO (n = 29) or placebo (n = 29). Despite modest increases in CO blood levels, the change in MMP7 concentrations after 12 weeks of treatment did not significantly differ between the study arms (MMP7 difference at week 12, -0.90 ng/mL; 95% CI, -4.18 to 2.38 ng/mL). No differences were observed in physiologic measures, incidence of acute exacerbations, hospitalization, death, or patient-reported outcomes. Importantly, no differences in distribution of adverse events were noted between the treatment arms.

CONCLUSIONS: Inhaled CO is well tolerated and can be safely administered to patients with IPF in the ambulatory setting; however, inhaled CO did not result in significant changes in study end points. Our findings support testing the efficacy of inhaled therapies in future IPF clinical trials.

TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01214187; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Rosas IO, Goldberg HJ, Collard HR, et al. A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest. 2017. PMID: 29100885. doi:10.1016/j.chest.2017.09.052

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。